SPEGRA combines three agents that inhibit viral replication at multiple points, offering robust control over HIV-1. The once-daily dosing enhances adherence and improves clinical outcomes.
Recommended for:
Adults and adolescents (≥ 35 kg) with HIV-1
Patients initiating or continuing ART
Individuals needing a long-term, simplified regimen
Those aiming for sustained viral suppression
HIV-1 infection treatment in adults and adolescents weighing ≥ 35 kg, as part of combination antiretroviral therapy
Take one tablet orally once daily, with or without food. For optimal results, maintain consistent daily use and avoid missed doses.
Contraindications:
Known hypersensitivity to any ingredient
Co-administration with dofetilide
Severe hepatic impairment
Side Effects:
Headache, insomnia
Nausea, abdominal pain
Elevated liver enzymes
Lipid profile changes
Hypersensitivity reactions
